NCT06554470

Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy

Local Versus Systemic Methotrexate in Management of Uterine Ectopic Pregnancy: A Randomized Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for further management options.

Detailed description

Ectopic pregnancy is considered a life-threatening condition which requires immediate intervention. Owing to the advancements in medical technology, ectopic pregnancy can now be diagnosed in the early stages. Methotrexate (MTX) is an antimetabolite drug showing a competitive reversible binding concerning natural dihydrofolates and acting as an inhibitor of the dihydrofolate-reductase (DHFR), a key enzyme synthesizing the tetrahydrofolates needed for the synthesis of purine and pyrimidine rings.

Conditions

• Local
• Systemic
• Methotrexate
• Uterine Ectopic Pregnancy

Interventions

Type	Name	Description
DRUG	Systemic Methotrexate	Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
DRUG	Local Methotrexate	Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).

Timeline

• Start date: 2024-08-15
• Primary completion: 2025-07-01
• Completion: 2025-07-01
• First posted: 2024-08-15
• Last updated: 2024-08-16

Locations

1 site across 1 country: Egypt